



Glucose Variability Assessed with Continuous
Glucose Monitoring
Citation for published version (APA):
Foreman, Y. D., Brouwers, M. C. G. J., van der Kallen, C. J. H., Pagen, D. M. E., van Greevenbroek, M.
M. J., Henry, R. M. A., Koster, A., Wesselius, A., Schaper, N. C., & Stehouwer, C. D. A. (2020). Glucose
Variability Assessed with Continuous Glucose Monitoring: Reliability, Reference Values, and Correlations
with Established Glycemic Indices-The Maastricht Study. Diabetes Technology & Therapeutics, 22(5),
395-403. https://doi.org/10.1089/dia.2019.0385





Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 03 Nov. 2021
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Glucose Variability Assessed with Continuous
Glucose Monitoring:
Reliability, Reference Values, and Correlations
with Established Glycemic Indices—The Maastricht Study
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Abstract
Background: Glucose variability (GV) measured by continuous glucose monitoring (CGM) has become an
accepted marker of glycemic control. Nevertheless, several methodological aspects of GV assessment require
further study. We, therefore, investigated the minimum number of days needed to reliably measure GV,
assessed GV reference values, and studied the correlation of GV with established glycemic indices (i.e., HbA1c,
seven-point oral glucose tolerance test [OGTT]-derived indices).
Methods: We used cross-sectional data from The Maastricht Study, an observational population-based cohort
enriched with type 2 diabetes. Participants with more than 48 h of CGM (iPro2; Medtronic) were included for
analysis (n = 851; age: 60 – 9years; 49% women; 23% type 2 diabetes). We used mean sensor glucose (MSG),
standard deviation (SD), and coefficient of variation (CV) as CGM-derived indices (the latter two for GV
quantification). We calculated reliability using the Spearman–Brown prophecy formula, established reference
values by calculating 2.5th–97.5th percentiles, and studied correlations using Spearman’s rho.
Results: Sufficient reliability (R > 0.80) was achieved with two (MSG and SD), or three monitoring days (CV).
The reference ranges, assessed in individuals with normal glucose metabolism (n = 470), were 90.5–
120.6 mg/dL (MSG), 7.9–24.8 mg/dL (SD), and 7.74%–22.45% (CV). For MSG, the strongest correlation was
found with fasting plasma glucose (rho = 0.65 [0.61; 0.69]); for SD, with the 1-h OGTT value (rho = 0.61 [0.56;
0.65]); and for CV, with both the incremental glucose peak (IGP) during the OGTT (rho = 0.50 [0.45; 0.55]) and
the 1-h OGTT value (rho = 0.50 [0.45; 0.55]).
Conclusions: The reliability findings and reference values are relevant for studies that aim to investigate CGM-
measured GV. One-hour OGTT and IGP values can be used as GV indices when CGM is unavailable.
Keywords: Continuous glucose monitoring, Epidemiology, Glucose variability, Oral glucose tolerance test,
Reference values, Reliability, Type 2 diabetes mellitus.
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Daily glucose variability (GV) is thought to contrib-ute to the development of diabetes-related complica-
tions irrespective of mean glycemia,1 and, hence, is accepted
as a valuable marker of glycemic control.2 Continuous glu-
cose monitoring (CGM) is the preferred method for mea-
suring GV, as it is able to assess many of its aspects (i.e.,
amplitude, frequency, and duration of fluctuations),2 whereas
other measures (e.g., oral glucose tolerance test [OGTT],
repeated self-measurement of blood glucose [SMBG]) only
assess singular aspects. CGM is, however, a challenging
technology to use in a large epidemiological setting, in part
due to its costliness and relative invasiveness.3
Despite prior efforts, several methodological aspects of
GV measurement with CGM need further investigation. First,
the required number of days to reliably measure daily GV is
unclear for individuals with normal glucose metabolism
(NGM), prediabetes, or type 2 diabetes. Second, there is
currently little information on GV reference values, which
are ideally determined in healthy individuals, that is, indi-
viduals with NGM.4 Third, little is known about the rela-
tionship of GV with established glycemic indices, such as
fasting plasma glucose (FPG), OGTT-derived indices, and
HbA1c. Certain OGTT-derived indices may give a good ap-
proximation of GV and could thus be used as alternatives in
an epidemiological setting when CGM is not available.
We, therefore, (1) investigated the minimum number of
days needed to reliably measure GV with CGM; (2) assessed
GV reference values according to glucose metabolism status
(GMS); and (3) studied the correlation of CGM-measured
GV with established glycemic indices, in a large population-
based cohort.
Research Design and Methods
Study population and design
We used data from The Maastricht Study, an observa-
tional, prospective, population-based cohort study. The ra-
tionale and methodology have been described previously.5 In
brief, The Maastricht Study focuses on the etiology, patho-
physiology, complications, and comorbidities of type 2 dia-
betes, and is characterized by an extensive phenotyping
approach. All individuals between 40 and 75 years of age and
living in the southern part of the Netherlands were eligible for
participation. Participants were recruited through mass media
campaigns and from the municipal registries and the regional
Diabetes Patient Registry through mailings. For reasons of
efficiency, recruitment was stratified according to known
type 2 diabetes status, with an oversampling of individuals
with type 2 diabetes. The Maastricht Study has been ap-
proved by the Institutional Medical Ethics Committee
(NL31329.068.10) and the Minister of Health, Welfare, and
Sports of the Netherlands (Permit 131088-105234-PG). All
participants gave written informed consent.
Continuous glucose monitoring
From September 19, 2016 until September 13, 2018, all
participants were invited to undergo CGM (iPro2 and Enlite
Glucose Sensor; Medtronic, Tolochenaz, Switzerland) as a
part of their standard measurements. To ensure inclusion of a
sufficient number of participants with prediabetes and type 2
diabetes within a reasonable timeframe, we reinvited a pre-
diabetes- and type 2 diabetes-enriched group of partici-
pants—who had visited The Maastricht Study between
January 2015 until September 2016 for standard measure-
ments—to undergo CGM as a separate research visit (further
referred to as ‘‘catch-up visit’’). The CGM device was worn
on the lower abdomen and recorded subcutaneous interstitial
glucose values (range: 40–400 mg/dL) every 5 min for a 7-
day period. During this time, participants were asked to
perform SMBG with the use of Contour Next (Ascensia
Diabetes Care, Mijdrecht, the Netherlands) four times daily
(i.e., before main meals and at bedtime). These SMBG values
were used to retrospectively calibrate the CGM values at the
moment of data upload to CareLink iPro (Medtronic). Ac-
curacies (expressed as the mean absolute relative difference)
of the iPro2 and Contour Next are 11.0%6 and 3.1%–5.6%,7–9
respectively. Participants were blinded to the CGM record-
ing, but not to SMBG values. Diabetes medication use was
allowed and no dietary or physical activity instructions were
given.
We used the Glycemic Variability Research Tool (Gly-
VaRT; Medtronic) software to process CGM data. First, the
first 24 h of glucose values were removed, because of insuf-
ficient calibration. Next, we excluded individuals of whom
less than 24 h of recording (less than one data day) remained.
Then, we calculated mean sensor glucose (MSG), standard
deviation (SD), and coefficient of variation (CV; SD/MSG ·
100%) for each period of 24 h (data day) and for the total
recording period. Based on international consensus, we used
SD and CV as indices of GV.2 We additionally included
MSG in our analyses, as GV indices are preferably inter-
preted in the context of mean glucose values.3 As described in
the Supplementary Methods, we also calculated other com-
monly used GV indices with the use of GlyVaRT.
Oral glucose tolerance test
Participants underwent a standardized 2-h 75 gram OGTT
after fasting overnight to determine GMS, which was defined
according to the World Health Organization 2006 criteria as:
(1) NGM, (2) impaired fasting glucose and impaired glucose
tolerance (combined as prediabetes), or (3) type 2 diabetes.10
For safety reasons, individuals using insulin or with a fasting
glucose level above 198 mg/dL, as determined by a finger
prick, did not undergo an OGTT. For these participants, we
determined GMS based on FPG and information about their
diabetes medication. During the OGTT, we took venous
blood glucose samples at baseline ( = FPG) and at 15, 30, 45,
60, 90, and 120 min. In individuals with complete OGTT
data, we calculated the incremental glucose peak (IGP) by
subtracting FPG from the highest OGTT glucose value
( = maximum glucose peak).
Measurement of covariates
As described previously,5 we assessed diabetes duration
by questionnaire; assessed use of glucose-lowering medica-
tion as part of a medication interview; measured weight,
height, and body mass index (BMI) during a physical ex-
amination; and measured HbA1c in fasting venous blood.
Body weight and glucose-lowering medication use were re-
assessed in individuals who attended a CGM catch-up visit.





















































To determine the minimum number of CGM days required
for a reliable assessment of MSG, SD, and CV, we calculated
GMS-stratified reliability (R) with the use of the Spearman–
Brown prophecy formula: R =sB2/(sB2 + [sW2/n]), where
sB is the interindividual variance, sW is the intraindividual
variance, and n is the number of consecutive monitoring
days.11,12 We used variance component analysis through
ANOVA with the different CGM-derived indices as the de-
pendent variable to estimate the participant variance com-
ponent (interindividual; sB) and the residual variance
component (intraindividual; sW). For these analyses we in-
cluded only individuals with more than five complete data
days of CGM to ensure optimal reliability. A R of >0.80 was
considered reliable.11
We calculated the distribution of MSG, SD, and CV values
(10th–90th, 5th–95th, and 2.5th–97.5th percentile) in GMS-
stratified groups. We established reference ranges based on
the 2.5th–97.5th percentile of individuals with NGM.4 As an
additional analysis, we calculated the distributions for sex-
and age-stratified GMS groups. In addition, MSG, SD, and
CV differences between GMS groups were statistically
compared with the use of ANOVA with post-hoc Bonferroni
correction.
A Spearman’s rank test was used to determine the corre-
lation (rho) and 95% confidence interval of CGM-derived
indices with FPG, OGTT-derived indices (i.e., 15-, 30-, 45-,
60-, 90-, and 120-min glucose values, maximum glucose
peak, and IGP), and HbA1c. As an additional analysis, we
used linear regression to calculate unadjusted regression
coefficients and their corresponding 95% confidence inter-
vals for the glycemic indices that correlated most strongly
with MSG, SD, and CV.
Additionally, several sensitivity analyses were performed:
(1) after exclusion of individuals with less than the reliable
number of CGM days; (2) after exclusion of individuals who
underwent CGM as part of a catch-up visit; and (3) after
exclusion of the individuals with data gaps during CGM re-
cording. In addition, the main analyses were also carried out
for other commonly used GV indices (i.e., mean amplitude of
glucose excursions [MAGE], interquartile range [IQR], and
mean of daily differences [MODD]).
Normally distributed data are presented as mean and SD,
non-normally distributed data as median and IQR, and cate-
gorical data as n (%). We considered a P value of <0.05 as
statistically significant. All statistical analyses were per-
formed with the Statistical Package for Social Sciences
(version 25.0; IBM, Chicago, IL).
Results
Study population characteristics
The total CGM study population comprised 896 individ-
uals, from which we excluded two participants with diabetes
types other than type 2 diabetes. Next, due to the removal of
the first 24 h of CGM data, we excluded 27 individuals with
<24 h of CGM, as for them CGM-derived indices could not
be calculated. Then, we excluded individuals (n = 16) who
had less than one data day (24 h) of CGM remaining, which
resulted in the final study population that consisted of 851
individuals (Supplementary Fig. S1).
Table 1 shows the GMS-stratified participant characteris-
tics of the final study population, based on the regular study
visit measurements. With deteriorating GMS, participants
were older, more often male, had a higher BMI, and had
higher HbA1c, FPG, and OGTT-derived index values. In-
dividuals with type 2 diabetes were often newly diagnosed by
OGTT. More than half of the participants with type 2 diabetes
used metformin as their primary diabetes medication
(n = 104, 53.1%); insulin use was uncommon (n = 19, 9.6%).
Most participants (n = 772, 90.7%) completed the 7-day
recording period, which resulted in six data days of usable
CGM data (Supplementary Table S1). A large number of
individuals (n = 721, 84.7%) also had five or more consecu-
tive, complete days of CGM. Several participants (n = 66,
7.8%) experienced at least one period during which no glu-
cose values were recorded (i.e., a data gap), the length of
which varied considerably (median: 5.3 h [IQR: 0.9–19.6]).
SMBG adherence was high (i.e., median average daily cali-
bration frequency: 4.0 [3.7–4.1], Supplementary Table S1).
Of the final study population (n = 851), 603 participants
(70.9%) underwent CGM as part of their standard mea-
surements (i.e., regular visits) and 248 participants (29.1%)
during a catch-up visit. Supplementary Table S2 shows
the participant characteristics stratified for research visit.
Participant characteristics were generally comparable after
stratification for GMS. The median time between the regular
and catch-up visit was 2.1 [2.0–2.2] years (Supplementary
Table S3). Only individuals with prediabetes had gained
weight between their regular and catch-up visit (from
82.9 – 15.6 to 84.1 – 16.2 kg, P = 0.011); large differences in
body weight (>10%) were rare (n = 12, 4.8%). Use of glucose-
lowering medication was more frequent in individuals with
type 2 diabetes at the catch-up visit (71.8% vs. 63.7% at the
regular and catch-up visit, respectively, P = 0.035).
Reliability of continuous glucose monitoring
In the reliability analyses, individuals with more than five
consecutive, complete days of CGM recording were included
(n = 721, 84.7%) (Supplementary Tables S1 and S4). Figure 1
illustrates the reliability for different CGM-derived indices
per number of consecutive monitoring days in individuals
with NGM, prediabetes, or type 2 diabetes. In case of MSG
(Fig. 1; panel A) and SD (Fig. 1; panel B), the reliability was
sufficient (R > 0.80) after 1 day of recording for individuals
with prediabetes and type 2 diabetes, and after 2 days for
individuals with NGM. In case of CV (Fig. 1; panel C), the
reliability was sufficient after 2 days of recording for indi-
viduals with NGM and type 2 diabetes, and after 3 days for
individuals with prediabetes.
GV according to glucose metabolism status
Table 2 shows the GMS-stratified median, mean, and
various percentile values for MSG, SD, and CV. Deteriorat-
ing GMS was associated with statistically significantly higher
MSG, SD, and CV values (even after Bonferroni correction).
The distributions (10th–90th, 5th–95th, 2.5th–97.5th per-
centiles) of MSG, SD, and CV were broader as GMS deteri-
orated. The reference values for MSG, SD, and CV, based on
the 2.5th–97.5th percentiles of individuals with NGM, were
90.5–120.6 mg/dL (5.03–6.69 mM), 7.9–24.8 mg/dL (0.44–
1.37 mM), and 7.74%–22.45%, respectively. Distributions of




















































MSG, SD, and CV were not materially different for age- and
sex-stratified GMS groups (Supplementary Table S5).
Correlations with established glycemic indices
Figure 2 and Supplementary Table S6 depict the Spearman
correlation coefficients of MSG, SD, and CV with FPG,
OGTT-derived indices, and HbA1c. Since a complete seven-
point OGTT was not available in all individuals, the number
of individuals included in these correlation analyses varied
from 744 to 851 (Supplementary Table S6). Correlations with
MSG and SD were generally stronger than those with CV.
For MSG, the strongest correlation was found with FPG
(rho = 0.65 [0.61; 0.69]), followed by HbA1c (rho = 0.63
[0.58; 0.67]) and maximum glucose peak (rho = 0.63 [0.59;
0.67]). For both SD and CV, a similar pattern was observed
regarding the OGTT time points: the strongest correlations
were found with the 1-h OGTT value and correlations were
gradually weaker for the time points that were more distant
from this OGTT value. For SD, we found the highest corre-
lation coefficient with the 1-h OGTT value (rho = 0.61 [0.56;
0.65]); for CV, with both IGP (rho = 0.50 [0.45; 0.55]) and the
1-h OGTT value (rho = 0.50 [0.45; 0.55]). Of note, the 1-h
OGTT value did not necessarily represent the glucose peak
time point during the OGTT. In fact, with deteriorating GMS,
the peak time point appeared to shift to a later moment during
the OGTT (Supplementary Table S7).
Supplementary Table S8 shows GMS-stratified Spearman
correlation coefficients. We found that MSG correlated best
with FPG in individuals with NGM (rho = 0.37 [0.29; 0.44]),
and with HbA1c in individuals with prediabetes (rho = 0.46
[0.34; 0.57]) and type 2 diabetes (rho = 0.60 [0.50; 0.68]). SD
correlated best with IGP (rho = 0.31 [0.22; 0.39]) and maxi-
mum glucose peak (rho = 0.30 [0.22; 0.39]) in individuals
with NGM, with the 90-min OGTT value (rho = 0.30 [0.16;
0.43]) and HbA1c (rho = 0.30 [0.17; 0.43]) in individuals with
prediabetes, and with the 90-min OGTT (rho = 0.54 [0.42;
0.65]) value, IGP (rho = 0.54 [0.42; 0.65]) and maximum
glucose peak (rho = 0.54 [0.41; 0.64]) in individuals with type
2 diabetes. We observed that CV correlated best with IGP
in individuals with NGM (rho = 0.25 [0.16; 0.34]), with the
90-min (rho = 0.23 [0.09; 0.37]) and 2-h (rho = 0.24 [0.09;
0.37]) OGTT value in individuals with prediabetes, and
with IGP (rho = 0.49 [0.35; 0.60]) in individuals with type 2
diabetes.
Supplementary Table S9 displays the regression coeffi-
cients of the five glycemic indices that correlated most
strongly with MSG, SD, and CV in the total study population.
In addition, it shows GMS-stratified regression coefficients of
the three glycemic indices that correlated best with MSG, SD,
and CV in individuals with NGM, prediabetes, and type 2
diabetes.
Additional analyses
The reliability for MSG, SD, and CV was not materially
different after exclusion of participants who returned for the
catch-up visit (Supplementary Fig. S2). After exclusion of in-
dividuals with less than the reliable amount of recording days,
exclusion of individuals who returned for the catch-up visit
Table 1. Participant Characteristics of the Total Study Population and of Glucose Metabolism
Status-Stratified Groups
Characteristic Total (N = 851) NGM (n = 470) PreD (n = 184) T2D (n = 197)
Age, years 59.9 – 8.7 58.2 – 8.8 61.5 – 8.1 62.4 – 7.8
Women, n (%) 418 (49.1) 266 (56.6) 83 (45.1) 69 (35.0)
BMI, kg/m2 27.2 – 4.4 25.6 – 3.6 28.5 – 4.4 29.7 – 4.7
Newly diagnosed T2D, n (%) 70 (8.2) — — 70 (35.5)
HbA1c, % 5.7 – 0.8 5.4 – 0.3 5.6 – 0.4 6.7 – 1.0
HbA1c, mmol/mol 39.1 – 8.3 35.4 – 3.4 37.8 – 4.2 49.2 – 10.8
FPG, mg/dL 97.3 [90.1–111.7] 91.9 [86.5–97.3] 108.1 [97.3–113.5] 131.5 [117.1–151.3]
OGTT-derived indices, mg/dL
15-min 129.7 [117.1–149.5] 120.7 [111.7–131.5] 138.7 [126.1–153.1] 169.4 [151.3–185.6]
30-min 157.6 [135.6–189.2] 140.5 [126.1–158.5] 176.6 [156.7–191.0] 214.4 [192.8–237.8]
45-min 165.7 [135.1–212.6] 142.3 [120.3–162.1] 192.8 [174.8–219.8] 252.2 [221.6–282.9]
1-h 160.3 [120.7–216.2] 127.9 [102.7–154.9] 198.2 [174.8–224.3] 270.2 [232.4–306.3]
90-min 138.7 [104.5–200.9] 111.7 [93.7–131.5] 178.4 [156.7–203.6] 280.1 [238.3–321.6]
2-h 120.7 [93.7–163.9] 99.1 [84.7–115.3] 151.3 [135.1–165.7] 245.0 [210.8–291.9]
Maximum glucose peak 175.7 [145.9–227.0] 149.5 [133.3–168.0] 205.4 [185.6–227.0] 288.3 [241.7–325.6]
IGP 77.5 [52.2–120.3] 57.7 [39.6–75.7] 101.8 [77.5–122.5] 161.2 [129.7–185.6]
Diabetes medication use, n (%) 109 (12.8) — — 109 (55.6)
Insulin 19 (2.2) — — 19 (9.6)
Metformin 104 (12.2) — — 104 (53.1)
Sulfonylureas 21 (2.5) — — 21 (10.7)
Thiazolidinediones 0 (0) — — 0 (0)
GLP-1 analogs 3 (0.4) — — 3 (1.5)
DDP-4 inhibitors 1 (0.1) — — 1 (0.5)
Data are reported as mean – SD, median (IQR), or number (percentage [%]) as appropriate. Data represent the study population of
participants with at least 48 h of CGM data.
BMI, body mass index; CGM, continuous glucose monitoring; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide-1; HbA1c,
glycated hemoglobin A1c; IGP, incremental glucose peak; IQR, interquartile range; NGM, normal glucose metabolism; OGTT, oral glucose
tolerance test; PreD, prediabetes; SD, standard deviation; T2D, type 2 diabetes.




















































or exclusion of individuals with recording data gaps, all CGM-
derived indices (MSG, SD, and CV) still differed statistically
significantly between individuals with NGM, prediabetes, or
type 2 diabetes (Supplementary Tables S10–S12). The distri-
butions of MSG, SD, and CV were generally comparable
after exclusion of individuals with less than the reliable
amount of recording days, exclusion of individuals who re-
turned for the catch-up visit or exclusion of individuals with
recording data gaps (Supplementary Tables S10–S12).
No substantially different Spearman correlation coeffi-
cients were obtained after exclusion of individuals with less
than the reliable number of recording days (Supplementary
Fig. S3) or with recording data gaps (Supplementary Fig. S4).
Although exclusion of individuals who returned for a catch-
up visit resulted in lower correlation coefficients (0.1–0.2 on
average), it did not affect the original correlation patterns
that were observed for the correlations of MSG, SD, and
CV with FPG, OGTT-derived indices, and HbA1c (Supple-
mentary Fig. S5). Last, the reliability, reference value, and
correlation results of MAGE, IQR, and MODD are shown in
the Supplemental materials (Supplementary Figs. S6 and S7;
Supplementary Table S13).
Discussion
We investigated—in individuals with NGM, prediabetes,
or type 2 diabetes—the minimum number of days needed to
reliably measure CGM-derived indices, assessed their refer-
ence values, and studied their relationship with several es-
tablished glycemic indices. Our study has three main
findings. First, a reliable assessment of MSG, SD, and CV can
be made with two to three recording days. Second, MSG, SD,
and CV reference values were obtained based on individuals
with NGM. Third, GV indices correlated most strongly with
the 1-h OGTT value, IGP, and maximum glucose peak.
In our study population, the common 7-day recording
period—with six functional CGM days—yielded high reli-
ability, especially for MSG. In addition, a reliable assessment
(R > 0.80) of CGM-derived indices could be made with rel-
atively few days: 2 days of monitoring in case of MSG and
SD, 3 days in case of CV. Our conclusion contrasts with the
sampling duration findings of comparable studies (i.e., 12–15
days are minimally required).13–15 However, comparison is
complicated by the fact that all prior research was performed
in individuals with type 1 diabetes. Since this group is
characterized by larger day-to-day differences in their gly-
cemic profiles (i.e., higher intraindividual variance),16 a
longer sampling duration is presumably required to achieve
sufficient reliability. The differences in statistical methods
(i.e., correlation, percentage difference analyses) and cutoff
values (i.e., r2 > 0.70–0.86; overall difference <10%) used,
further hamper comparison.
In line with several other studies, we found that MSG
and SD values were statistically significantly higher with
deteriorating GMS17–20; more interestingly, we observed
statistically significantly higher CV values as well. Since CV
quantifies GV adjusted for MSG, it can be concluded that GV
is higher in individuals with type 2 diabetes as compared with
prediabetes and NGM, regardless of the mean glucose value.
The MSG, SD, and CV values observed in the present study
were generally lower than previously reported.17–19 In con-
trast to the current study, some of these studies did not ob-
serve statistically significant differences between individuals
with NGM and prediabetes,17,19 which could be attributed to
their relatively small sample sizes (n = 50–162).
We established reference values for MSG, SD, and CV
based on the 2.5th–97.5th percentiles of individuals with
NGM, which is preferred when reporting reference inter-
vals.4 While Bode et al. first aimed to establish normative
values in individuals with type 2 diabetes,16 Zhou et al. were
the first to report the distribution (5th–95th percentile) of
FIG. 1. Reliability for MSG (A), SD (B), and CV (C) per
number of consecutive continuous glucose monitoring days
in individuals with NGM, prediabetes, or type 2 diabetes.
The dashed horizontal line represents the cutoff for suffi-
cient reliability (R > 0.80). CV, coefficient of variation;
MSG, mean sensor glucose; NGM, normal glucose metab-
olism; PreD, prediabetes; SD, standard deviation; T2D, type
2 diabetes.




















































MSG (84.5–118.9 mg/dL) and SD (6.3–25.2 mg/dL) in indi-
viduals with NGM.21,22 These values were, however, not
determined under normal living conditions, as the partici-
pants were given dietary instructions as part of the study
design. This could explain the lower 5th percentile values for
both indices. Gude et al. also reported on SD (5th–95th
percentile) in a population-based cohort of Caucasian indi-
viduals with and without type 2 diabetes (13.0–87.0 mg/dL
and 9.0–24.0 mg/dL, respectively).23 Although they did not
specifically report reference ranges for NGM, their distribu-
tions were generally comparable to ours, except for the
substantially higher 95th percentile they observed in indi-
viduals with type 2 diabetes, who had a higher mean HbA1c
(54.0 – 10.8 mmol/mol) and more frequently used oral
glucose-lowering drugs (86%) and insulin (21%).
Of all glycemic indices, MSG correlated best, although
moderately, with FPG, maximum glucose peak, and HbA1c.
Zhou et al. previously reported similar correlations coeffi-
cients for MSG with FPG and HbA1c.
24 We additionally
found that, of all glycemic indices, the strongest correlations
of SD and CV were observed with the 1-h OGTT value,
maximum glucose peak, and IGP. The GMS-stratified cor-
relation coefficients were generally lower than those for the
total study population, which can be attributed to the effect of
range restriction (i.e., the smaller ranges in the subgroups
attenuate the correlation coefficients).25 Interestingly, not
only SD, but also CV correlated quite moderately with in-
dices of mean glycemia (i.e., FPG, HbA1c). This may explain
the difficulty of establishing effects of specific GV im-
provements while maintaining similar HbA1c, FPG, or MSG
concentrations.26
The correlations found with SD and CV legitimate the
use of the 1-h or peak glucose value during an OGTT to
approximate GV if CGM is unavailable (e.g., in a large
observational study27). This sheds an interesting light on
prior research that found that the 1-h OGTT value was as-
sociated with cardiovascular disease and mortality.28
Nevertheless, we observed that the strength of the correla-
tion with GV indices was determined by the time point of
the OGTT peak. The 1-h OGTT value was often not re-
flective of the glucose peak, especially in individuals with
NGM (15.3%) and T2D (20.3%) (Supplementary Tables S7
and S8). Accordingly, if the total study population and
GMS-stratified groups are taken together, IGP generally
correlated most strongly with SD and CV. This suggests that
IGP, rather than the 1-h OGTT value, is the preferred
OGTT-derived index to use as GV proxy.
Our findings have important implications for the study of
GV. First, the CGM period may be shortened to three func-
tional days of recording for individuals with NGM, predia-
betes, or type 2 diabetes to alleviate participant burden
without compromising reliability of GV assessment. Im-
portantly, a longer recording period may be required in in-
dividuals with type 2 diabetes who are treated with multiple
daily insulin injections (not highly represented in this study).
In addition, a reliable assessment of other CGM-derived in-
dices (e.g., time in range) could require more recording days.
Second, our reference ranges can be used to classify indi-
viduals as having normal or abnormal MSG, SD, or CV
values. However, these reference values need not necessarily
represent target values, as is the case for HbA1c.
29 Third, IGP
should be viewed as the preferred OGTT-derived index to
assess GV, since it correlated most strongly with SD and CV
for both the total study population and the GMS-stratified
groups. Last, the regression coefficients found could be used
to approximate CGM-derived indices based on several es-
tablished glycemic indices (Supplementary Table S9).
This study has several strengths and limitations. Strengths
are (1) the large, population-based study sample; (2) the high
overall SMBG adherence, ensuring adequate CGM calibra-
tion; (3) the OGTT-based assessment of GMS, allowing the
calculation of reference values; (4) the availability of a seven-
Table 2. Distribution of Mean Sensor Glucose, Standard Deviation and Coefficient of Variation
in Glucose Metabolism Status-Stratified Groups
CGM-derived index NGM (n = 470) PreD (n = 184) T2D (n = 197) P
MSG, mg/dL
Median [IQR] 105.0 [99.8–110.1] 112.3 [104.7–119.4]* 135.7 [122.6–156.9]*{ <0.001
Mean – SD 105.1 – 7.5 113.7 – 13.7 141.6 – 29.7
10th–90th percentile 95.7–114.8 100.2–127.3 109.5–177.1
5th–95th percentile 92.8–117.9 95.3–135.9 104.2–210.7
2.5th–97.5th percentile 90.5–120.6 90.8–149.0 101.4–230.3
SD, mg/dL
Median [IQR] 13.1 [11.2–15.7] 16.2 [13.4–20.3]* 27.2 [20.4–35.0]*{ <0.001
Mean – SD 13.9 – 4.2 17.6 – 6.4 29.5 – 12.7
10th–90th percentile 9.5–19.6 11.6–23.5 15.8–44.5
5th–95th percentile 8.6–23.1 10.8–28.5 14.2–55.2
2.5th–97.5th percentile 7.9–24.8 9.9–34.3 11.9–61.9
CV, %
Median [IQR] 12.6 [10.8–14.9] 14.9 [12.2–17.5]* 19.3 [15.9–24.0]*{ <0.001
Mean – SD 13.2 – 3.6 15.3 – 4.3 20.5 – 6.6
10th–90th percentile 9.38–18.03 10.74–20.63 13.31–29.42
5th–95th percentile 8.49–20.66 10.15–24.04 12.32–33.35
2.5th–97.5th percentile 7.74–22.45 9.29–25.78 10.51–36.50
*P < 0.001 versus NGM.
{P < 0.001 versus PreD.
CV, coefficient of variation; MSG, mean sensor glucose.




















































point OGTT, enabling comparison with multiple time points;
and (5) the robustness of the results, as reflected by the
consistency of multiple sensitivity analyses. Our study had
certain limitations. First, the reliability analyses would ide-
ally have been based on a longer recording period than six
functional days, as this could have improved the assessment
of intraindividual variation. We were, however, limited by
our study design, which aimed to prevent excessive partici-
pant strain and was restricted by sensor lifespan.6 Second, we
focused mainly on SD and CV as indices of GV, while others
exist (e.g., IQR, MAGE). With the use of MSG, SD, and CV,
we assume a normal distribution of CGM-derived glucose
values, which is not necessarily true. Nevertheless, SD was
shown to have a smaller random sampling error than other
GV indices, is widely used and easily interpretable, and can
be adapted to the preferred MSG-adjusted GV index (i.e.,
CV).2,3 Additionally, the different CGM-derived GV indices
have been found to be strongly correlated.3 Accordingly, the
MAGE, IQR, and MODD findings were generally compa-
rable to the SD and CV results (Supplementary Figs. S6 and
S7; Supplementary Table S13). Third, the strength of the
correlation coefficients of our total study population could
have been underestimated due to the inclusion of individuals
who returned for a catch-up visit, as there was a median time
of 2.1 years between CGM and the measurement of the
OGTT and HbA1c values. While the correlations were in-
vestigated in only newly recruited individuals (Supplemen-
tary Fig. S5), their interpretation is hampered by range
restriction (i.e., lower number of individuals with prediabetes
and type 2 diabetes in the regular visit when compared with
the catch-up visit).25 Fourth, the fact that the individuals with
type 2 diabetes were relatively well controlled (i.e., mean
HbA1c: 49.2 – 10.8 mmol/mol) and uncommonly used insulin
(n = 19, 9.6%), may also have influenced our findings.
Namely, a wider range of glycemic control could have altered
the reliability of CGM-derived indices in individuals with
type 2 diabetes by affecting the inter- and intraindividual
variance ratio. Additionally, percentile distributions of the
CGM-derived indices are inherently determined by the gly-
cemic status of the included individuals. The generalizability
of our results is additionally affected by the age-restricted and
predominately Caucasian study population, and by the ab-
sence of individuals with type 1 diabetes.
In conclusion, we showed that a reliable assessment of
CGM-derived indices can be made with two to three re-
cording days. In addition, we established the reference ranges
for MSG, SD, and CV as 90.5–120.6 mg/dL (5.03–6.69 mM),
7.9–24.8 mg/dL (0.44–1.37 mM), and 7.74%–22.45%, re-
spectively. We additionally found that the 1-h OGTT value,
IGP, and maximum glucose peak correlated moderately with
GV indices. These findings are relevant for future studies that
aim to use CGM to measure GV, or current studies that only
have OGTT-derived indices at their disposal to assess GV.
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